Comparative Pharmacology
Head-to-head clinical analysis: HUMATIN versus TOBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMATIN versus TOBRAMYCIN.
HUMATIN vs TOBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death. Exhibits concentration-dependent bactericidal activity.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
5-7 mg/kg IV once daily; 2-4 mg/kg/day IV divided every 8 hours for synergy; 2-4 mg/kg IM divided every 8 hours; 3-5 mg/kg/day IV for cystic fibrosis. Inhalation: 300 mg every 12 hours (nebulizer). Intrathecal: 5-20 mg/day.
None Documented
None Documented
Clinical Note
moderateTobramycin + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Tobramycin."
Clinical Note
moderateTobramycin + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Tobramycin."
Clinical Note
moderateTobramycin + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Tobramycin."
Clinical Note
moderateTobramycin + Acetyldigitoxin
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
2–3 hours (normal renal function); prolonged to 24–60 hours in anuria. Clinical context: dosing interval must be adjusted for renal impairment to avoid accumulation and toxicity.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Renal excretion of unchanged drug via glomerular filtration: >90% within 24 hours. Minimal biliary/fecal elimination (<5%).
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Tobramycin."